Neuronetics (STIM) Competitors $1.20 +0.01 (+0.84%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.22 +0.02 (+1.83%) As of 05/22/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock STIM vs. CV, TLSI, SI, SGHT, and CARLShould you buy Neuronetics stock or one of its competitors? MarketBeat compares Neuronetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neuronetics include CapsoVision (CV), TriSalus Life Sciences (TLSI), Shoulder Innovations (SI), Sight Sciences (SGHT), and Carlsmed (CARL). These companies are all part of the "medical equipment" industry. STIM vs. CVSTIM vs. TLSISTIM vs. SISTIM vs. SGHTSTIM vs. CARLHow does Neuronetics compare to CapsoVision?Neuronetics (NASDAQ:STIM) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability. Does the media prefer STIM or CV? In the previous week, Neuronetics had 2 more articles in the media than CapsoVision. MarketBeat recorded 3 mentions for Neuronetics and 1 mentions for CapsoVision. Neuronetics' average media sentiment score of 1.42 beat CapsoVision's score of 0.00 indicating that Neuronetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CapsoVision 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate STIM or CV? Neuronetics presently has a consensus target price of $3.00, suggesting a potential upside of 150.00%. CapsoVision has a consensus target price of $8.50, suggesting a potential upside of 28.01%. Given Neuronetics' higher probable upside, analysts plainly believe Neuronetics is more favorable than CapsoVision.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuronetics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00CapsoVision 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Is STIM or CV more profitable? Neuronetics has a net margin of -24.48% compared to CapsoVision's net margin of -198.87%. CapsoVision's return on equity of 0.00% beat Neuronetics' return on equity.Company Net Margins Return on Equity Return on Assets Neuronetics-24.48% -139.83% -27.13% CapsoVision -198.87%N/A -136.03% Which has better earnings & valuation, STIM or CV? CapsoVision has lower revenue, but higher earnings than Neuronetics. CapsoVision is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuronetics$149.16M0.56-$39M-$0.54N/ACapsoVision$13.55M24.48-$25.32M-$2.34N/A Do institutionals and insiders believe in STIM or CV? 53.6% of Neuronetics shares are held by institutional investors. 8.4% of Neuronetics shares are held by company insiders. Comparatively, 2.3% of CapsoVision shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryNeuronetics beats CapsoVision on 9 of the 14 factors compared between the two stocks.How does Neuronetics compare to TriSalus Life Sciences?Neuronetics (NASDAQ:STIM) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends. Does the media prefer STIM or TLSI? In the previous week, TriSalus Life Sciences had 10 more articles in the media than Neuronetics. MarketBeat recorded 13 mentions for TriSalus Life Sciences and 3 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.42 beat TriSalus Life Sciences' score of 0.57 indicating that Neuronetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TriSalus Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Which has more volatility & risk, STIM or TLSI? Neuronetics has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Do institutionals & insiders hold more shares of STIM or TLSI? 53.6% of Neuronetics shares are held by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are held by institutional investors. 8.4% of Neuronetics shares are held by insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is STIM or TLSI more profitable? Neuronetics has a net margin of -24.48% compared to TriSalus Life Sciences' net margin of -60.85%. TriSalus Life Sciences' return on equity of 0.00% beat Neuronetics' return on equity.Company Net Margins Return on Equity Return on Assets Neuronetics-24.48% -139.83% -27.13% TriSalus Life Sciences -60.85%N/A -69.91% Which has stronger valuation & earnings, STIM or TLSI? Neuronetics has higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuronetics$149.16M0.56-$39M-$0.54N/ATriSalus Life Sciences$45.15M4.43-$39.23M-$1.41N/A Do analysts rate STIM or TLSI? Neuronetics presently has a consensus price target of $3.00, suggesting a potential upside of 150.00%. TriSalus Life Sciences has a consensus price target of $7.50, suggesting a potential upside of 130.06%. Given Neuronetics' higher probable upside, research analysts plainly believe Neuronetics is more favorable than TriSalus Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuronetics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00TriSalus Life Sciences 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 SummaryNeuronetics beats TriSalus Life Sciences on 9 of the 15 factors compared between the two stocks.How does Neuronetics compare to Shoulder Innovations?Neuronetics (NASDAQ:STIM) and Shoulder Innovations (NYSE:SI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings. Does the media prefer STIM or SI? In the previous week, Neuronetics had 2 more articles in the media than Shoulder Innovations. MarketBeat recorded 3 mentions for Neuronetics and 1 mentions for Shoulder Innovations. Neuronetics' average media sentiment score of 1.42 beat Shoulder Innovations' score of 0.62 indicating that Neuronetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Shoulder Innovations 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in STIM or SI? 53.6% of Neuronetics shares are held by institutional investors. 8.4% of Neuronetics shares are held by insiders. Comparatively, 29.0% of Shoulder Innovations shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is STIM or SI more profitable? Neuronetics has a net margin of -24.48% compared to Shoulder Innovations' net margin of -81.78%. Shoulder Innovations' return on equity of -35.11% beat Neuronetics' return on equity.Company Net Margins Return on Equity Return on Assets Neuronetics-24.48% -139.83% -27.13% Shoulder Innovations -81.78%-35.11%-20.58% Do analysts prefer STIM or SI? Neuronetics currently has a consensus target price of $3.00, indicating a potential upside of 150.00%. Shoulder Innovations has a consensus target price of $21.00, indicating a potential upside of 43.13%. Given Neuronetics' higher probable upside, equities analysts plainly believe Neuronetics is more favorable than Shoulder Innovations.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuronetics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Shoulder Innovations 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Which has preferable valuation and earnings, STIM or SI? Neuronetics has higher revenue and earnings than Shoulder Innovations. Neuronetics is trading at a lower price-to-earnings ratio than Shoulder Innovations, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuronetics$149.16M0.56-$39M-$0.54N/AShoulder Innovations$47.32M6.43-$40.36M-$166.96N/A SummaryNeuronetics beats Shoulder Innovations on 8 of the 14 factors compared between the two stocks.How does Neuronetics compare to Sight Sciences?Neuronetics (NASDAQ:STIM) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership. Does the media prefer STIM or SGHT? In the previous week, Neuronetics had 3 more articles in the media than Sight Sciences. MarketBeat recorded 3 mentions for Neuronetics and 0 mentions for Sight Sciences. Neuronetics' average media sentiment score of 1.42 beat Sight Sciences' score of 0.00 indicating that Neuronetics is being referred to more favorably in the media. Company Overall Sentiment Neuronetics Positive Sight Sciences Neutral Which has preferable earnings and valuation, STIM or SGHT? Sight Sciences has lower revenue, but higher earnings than Neuronetics. Sight Sciences is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuronetics$149.16M0.56-$39M-$0.54N/ASight Sciences$77.36M3.54-$38.43M-$0.71N/A Which has more volatility & risk, STIM or SGHT? Neuronetics has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market. Do institutionals & insiders have more ownership in STIM or SGHT? 53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by company insiders. Comparatively, 30.9% of Sight Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is STIM or SGHT more profitable? Neuronetics has a net margin of -24.48% compared to Sight Sciences' net margin of -46.83%. Sight Sciences' return on equity of -52.34% beat Neuronetics' return on equity.Company Net Margins Return on Equity Return on Assets Neuronetics-24.48% -139.83% -27.13% Sight Sciences -46.83%-52.34%-28.49% Do analysts recommend STIM or SGHT? Neuronetics currently has a consensus target price of $3.00, indicating a potential upside of 150.00%. Sight Sciences has a consensus target price of $8.31, indicating a potential upside of 65.26%. Given Neuronetics' higher possible upside, equities analysts clearly believe Neuronetics is more favorable than Sight Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuronetics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Sight Sciences 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.44 SummarySight Sciences beats Neuronetics on 8 of the 15 factors compared between the two stocks.How does Neuronetics compare to Carlsmed?Carlsmed (NASDAQ:CARL) and Neuronetics (NASDAQ:STIM) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk. Which has stronger earnings & valuation, CARL or STIM? Carlsmed has higher earnings, but lower revenue than Neuronetics. Carlsmed is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarlsmed$50.51M6.52-$29.63M-$2.51N/ANeuronetics$149.16M0.56-$39M-$0.54N/A Is CARL or STIM more profitable? Neuronetics has a net margin of -24.48% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat Neuronetics' return on equity.Company Net Margins Return on Equity Return on Assets Carlsmed-57.76% -60.74% -29.84% Neuronetics -24.48%-139.83%-27.13% Do analysts prefer CARL or STIM? Carlsmed currently has a consensus target price of $19.33, suggesting a potential upside of 59.65%. Neuronetics has a consensus target price of $3.00, suggesting a potential upside of 150.00%. Given Neuronetics' higher possible upside, analysts clearly believe Neuronetics is more favorable than Carlsmed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carlsmed 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40Neuronetics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer CARL or STIM? In the previous week, Neuronetics had 3 more articles in the media than Carlsmed. MarketBeat recorded 3 mentions for Neuronetics and 0 mentions for Carlsmed. Neuronetics' average media sentiment score of 1.42 beat Carlsmed's score of 0.00 indicating that Neuronetics is being referred to more favorably in the news media. Company Overall Sentiment Carlsmed Neutral Neuronetics Positive Do institutionals & insiders hold more shares of CARL or STIM? 53.6% of Neuronetics shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryNeuronetics beats Carlsmed on 9 of the 14 factors compared between the two stocks. Get Neuronetics News Delivered to You Automatically Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STIM vs. The Competition ExportMetricNeuroneticsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.51M$7.04B$6.43B$12.33BDividend YieldN/A1.68%2.76%5.28%P/E RatioN/A48.4421.0625.67Price / Sales0.5674.06553.4382.70Price / CashN/A24.9143.6856.73Price / Book4.806.5310.367.14Net Income-$39M$158.81M$3.56B$335.80M7 Day Performance-6.25%4.60%5.12%3.02%1 Month Performance-28.57%0.74%3.54%2.48%1 Year Performance-69.92%3.17%34.14%35.08% Neuronetics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STIMNeuronetics3.5782 of 5 stars$1.20+0.8%$3.00+150.0%-69.9%$83.51M$149.16MN/A180Positive NewsInsider TradeCVCapsoVision1.1505 of 5 stars$7.24-0.4%$8.50+17.4%N/A$360.91M$13.55MN/A90News CoverageTLSITriSalus Life Sciences3.5342 of 5 stars$4.63+2.0%$7.00+51.2%-41.4%$285.09M$45.15MN/A106SIShoulder Innovations4.2339 of 5 stars$13.24+0.2%$21.00+58.6%N/A$273.33M$47.32MN/A61SGHTSight Sciences3.6698 of 5 stars$4.95-6.8%$8.31+67.9%+57.2%$268.51M$77.36MN/A210 Related Companies and Tools Related Companies CV Competitors TLSI Competitors SI Competitors SGHT Competitors CARL Competitors PROF Competitors RXST Competitors OBIO Competitors ELMD Competitors SMTI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STIM) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredThis small stock could surge when SpaceX goes publicWhen SpaceX goes public, billions in capital won't just flow into one stock - it will flood the entire sector....NXT Wave Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuronetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
